<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389711</url>
  </required_header>
  <id_info>
    <org_study_id>IRE-274-10/11-1</org_study_id>
    <nct_id>NCT03389711</nct_id>
  </id_info>
  <brief_title>INCMNSZ - Rheumatoid Arthritis Cohort</brief_title>
  <acronym>IRAC</acronym>
  <official_title>INCMNSZ Early Rheumatoid Arthritis Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identify Rheumatoid Arthritis patients diagnose within first 12 months since the beginning of
      the disease related symptoms. Initiate proper treatment according to international standards
      in order to achieve remission/low disease activity status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Provide an standardized follow up by a multidisciplinary specialized team.

        -  Create a biological (blood) bank to develop future research projects.

        -  Create a database with the clinical, serologic, radiographic and functional status
           patients data.

        -  Define comorbidities and mortality causes.

        -  Begin an educational program to improve patient disease self-knowledge
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2004</start_date>
  <completion_date type="Anticipated">February 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease activity status</measure>
    <time_frame>During the first two years of follow up: the evaluations will be every 2 months. After those years: the evaluations will be every 2, 4 or 6 months depending on disease activity status.</time_frame>
    <description>Describe the disease activity score using DAS 28 ESR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome : HAQ (Health Assessment Questionnarie)</measure>
    <time_frame>During the first two years of follow up: the evaluations will be every 2 months. After those years: the evaluations will be every 2, 4 or 6 months depending on disease activity status.</time_frame>
    <description>To describe the changes in every visit in the HAQ score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome: RADAI (Rheumatoid Arthritis Disease Activity Index)</measure>
    <time_frame>During the first two years of follow up: the evaluations will be every 2 months. After those years: the evaluations will be every 2, 4 or 6 months depending on disease activity status.</time_frame>
    <description>To describe the changes in every visit in the RADAI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome : SF-36 (Short Form Health Survey)</measure>
    <time_frame>During the first two years of follow up: the evaluations will be every 2 months. After those years: the evaluations will be every 2, 4 or 6 months depending on disease activity status.</time_frame>
    <description>To describe the changes in every visit in the SF-36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of health care drop-out</measure>
    <time_frame>During the first two years of follow up: the evaluations will be every 2 months. After those years: the evaluations will be every 2, 4 or 6 months depending on disease activity status.</time_frame>
    <description>Identify and describe patients from an inception ongoing cohort with recent onset RA at inclusion, who dropped out of health care during their follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mayor Depressive Episodes (MDE)</measure>
    <time_frame>During the first two years of follow up: the evaluations will be every 2 months. After those years: the evaluations will be every 2, 4 or 6 months depending on disease activity status.</time_frame>
    <description>Investigate associations between major depressive episodes (MDE), concordance with therapy (CwT) and disease outcomes in rheumatoid arthritis patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Michigan Hand Outcome Questionnarie (MHQ</measure>
    <time_frame>During the first two years of follow up: the evaluations will be every 2 months. After those years: the evaluations will be every 2, 4 or 6 months depending on disease activity status.</time_frame>
    <description>To assess a variety of hand and upper extremity injuries related to Rheumatoid Arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH)</measure>
    <time_frame>During the first two years of follow up: the evaluations will be every 2 months. After those years: the evaluations will be every 2, 4 or 6 months depending on disease activity status.</time_frame>
    <description>To measure upper-extremity disability and symptoms</description>
  </secondary_outcome>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Early Rheumatoid Arthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>DMARD´s and multidisciplinary treatment</intervention_name>
    <description>At study enrollment, medical history, disease-specific autoantibodies, ACR 1987 classification criteria for RA were applied. Medical evaluations were standardized and included at least 66 swollen and 68 tender joint counts, acute reactant-phase determinations , patient and physician reported outcomes, comorbidity established by record review, and treatment assessments (name, dose and schedule of all drug they were taking) along with an evaluation of persistence, at six-month intervals.
Patients were evaluated by a single rheumatologist every two months during the first two years of follow-up, and every two, four or six months thereafter.
Also the following scores: Michigan Hand Outcome Questionnaire (MHQ), Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH),Mayor Depressive Episodes (MDE) was defined using the Mini International Neuropsychiatric Interview and the severity of depressive symptoms was assessed with the Beck Depression Inventory (BDI-II).</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples to asses serological status (rheumatoid arthritis antibodies)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) belongs
        to the National Institutes of Health of México. Patients enrolled in the Early arthritis
        cohort had a disease duration of &lt;1 year when first evaluated, and no specific rheumatic
        diagnosis except for RA. Patients had partial health coverage and paid for their
        physician's consultations, laboratory investigations and for their treatment that was
        prescribed by the rheumatologist in charge of the clinic, and was &quot;treat to target&quot;
        oriented.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥18 years old

          -  Fulfilled ACR 1987 classification criteria for RA

          -  Disease evolution of &lt;1 year when first evaluated, and no specific rheumatic diagnosis
             except for RA.

        Exclusion Criteria:

          -  Patients with another rheumatic disease, except Sjögren syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Pascual, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INCMNSZ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginia Pascual, MD</last_name>
    <phone>00525555734111</phone>
    <email>virtichu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irazú Contreras, Msc</last_name>
    <phone>00525555734111</phone>
    <email>protocolosar@live.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</name>
      <address>
        <city>Mexico City</city>
        <state>Tlalpan</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Pascual, MD</last_name>
      <email>virtichu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Contreras-Yáñez I, Pascual-Ramos V. Predictors of health care drop-out in an inception cohort of patients with early onset rheumatoid arthritis. BMC Musculoskelet Disord. 2017 Jul 28;18(1):321. doi: 10.1186/s12891-017-1670-6.</citation>
    <PMID>28754110</PMID>
  </results_reference>
  <results_reference>
    <citation>Contreras-Yáñez I, Guaracha-Basañez G, Ruiz-Domínguez D, Pascual-Ramos V. Patient's perspective of sustained remission in rheumatoid arthritis. BMC Musculoskelet Disord. 2017 Sep 2;18(1):379. doi: 10.1186/s12891-017-1717-8.</citation>
    <PMID>28865423</PMID>
  </results_reference>
  <results_reference>
    <citation>Romero-Guzmán AK, Menchaca-Tapia VM, Contreras-Yáñez I, Pascual-Ramos V. Patient and physician perspectives of hand function in a cohort of rheumatoid arthritis patients: the impact of disease activity. BMC Musculoskelet Disord. 2016 Sep 15;17:392. doi: 10.1186/s12891-016-1246-x.</citation>
    <PMID>27628666</PMID>
  </results_reference>
  <results_reference>
    <citation>Atisha-Fregoso Y, Lima G, Pascual-Ramos V, Baños-Peláez M, Fragoso-Loyo H, Jakez-Ocampo J, Contreras-Yáñez I, Llorente L. Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters Function. PLoS One. 2016 Jul 21;11(7):e0159556. doi: 10.1371/journal.pone.0159556. eCollection 2016.</citation>
    <PMID>27442114</PMID>
  </results_reference>
  <results_reference>
    <citation>Contreras-Yáñez I, Pascual-Ramos V. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther. 2015 Jul 11;17:177. doi: 10.1186/s13075-015-0697-z.</citation>
    <PMID>26162892</PMID>
  </results_reference>
  <results_reference>
    <citation>Galicia-Hernández G, Parra-Salcedo F, Ugarte-Martínez P, Contreras-Yáñez I, Ponce-de-León A, Pascual-Ramos V. Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):261-9. Epub 2016 Mar 3.</citation>
    <PMID>26939612</PMID>
  </results_reference>
  <results_reference>
    <citation>Parra-Salcedo F, Contreras-Yáñez I, Elías-López D, Aguilar-Salinas CA, Pascual-Ramos V. Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity. Arthritis Res Ther. 2015 Feb 20;17:34. doi: 10.1186/s13075-015-0549-x.</citation>
    <PMID>25889060</PMID>
  </results_reference>
  <results_reference>
    <citation>Cabrera-Marroquín R, Contreras-Yáñez I, Alcocer-Castillejos N, Pascual-Ramos V. Major depressive episodes are associated with poor concordance with therapy in rheumatoid arthritis patients: the impact on disease outcomes. Clin Exp Rheumatol. 2014 Nov-Dec;32(6):904-13. Epub 2014 Sep 5.</citation>
    <PMID>25190569</PMID>
  </results_reference>
  <results_reference>
    <citation>Sánchez T, Contreras-Yáñez I, Elías-López D, Aguilar Salinas CA, Pascual-Ramos V. Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2014 Jul-Aug;32(4):509-15. Epub 2014 Jul 8.</citation>
    <PMID>25005131</PMID>
  </results_reference>
  <results_reference>
    <citation>Pascual-Ramos V, Contreras-Yáñez I, Rivera-Hoyos P, Enríquez L, Ramírez-Anguiano J. Cumulative disease activity predicts incidental hearing impairment in patients with rheumatoid arthritis (RA). Clin Rheumatol. 2014 Mar;33(3):315-21. doi: 10.1007/s10067-014-2485-6. Epub 2014 Jan 18.</citation>
    <PMID>24435352</PMID>
  </results_reference>
  <results_reference>
    <citation>Pascual-Ramos V, Contreras-Yáñez I. Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient's perspective. BMC Musculoskelet Disord. 2013 Dec 1;14:336. doi: 10.1186/1471-2474-14-336.</citation>
    <PMID>24289729</PMID>
  </results_reference>
  <results_reference>
    <citation>Contreras-Yáñez I, Rull-Gabayet M, Vázquez-Lamadrid J, Pascual-Ramos V. Radiographic outcome in Hispanic early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. Eur J Radiol. 2011 Aug;79(2):e52-7. doi: 10.1016/j.ejrad.2011.03.036. Epub 2011 Apr 8.</citation>
    <PMID>21477956</PMID>
  </results_reference>
  <results_reference>
    <citation>Contreras-Yáñez I, Ponce De León S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci. 2010 Oct;340(4):282-90. doi: 10.1097/MAJ.0b013e3181e8bcb0.</citation>
    <PMID>20881757</PMID>
  </results_reference>
  <results_reference>
    <citation>Pascual-Ramos V, Contreras-Yañez I, Cabiedes-Contreras J, Rull-Gabayet M, Villa AR, Vázquez-Lamadrid J, Mendoza-Ruiz JJ. Hypervascular synovitis and American College of Rheumatology Classification Criteria as predictors of radiographic damage in early rheumatoid arthritis. Ultrasound Q. 2009 Mar;25(1):31-8. doi: 10.1097/RUQ.0b013e3181981df0.</citation>
    <PMID>19276959</PMID>
  </results_reference>
  <results_reference>
    <citation>Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther. 2009;11(1):R26. doi: 10.1186/ar2620. Epub 2009 Feb 19.</citation>
    <PMID>19228421</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Virginia Pascual Ramos</investigator_full_name>
    <investigator_title>Lead Investigator of the Rheumatoid Arthritis Clinic</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis Mexico</keyword>
  <keyword>Early Rheumatoid Arthritis Cohort Mexico</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is undecided yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

